Brief: Journey Medical Corporation Expects Topline Results FromPhase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 For The Treatment Of Papulopustular Rosacea To Be Announced Week Of July 10
03/07/2023 13:12
July 3 (Reuters) - Journey Medical Corp DERM.O :
* JOURNEY MEDICAL CORPORATION EXPECTS TOPLINE RESULTS FROM
THE
PHASE 3 CLINICAL TRIALS (MVOR-1 AND MVOR-2) EVALUATING DFD-29
(MINOCYCLINE HYDROCHLORIDE MODIFIED RELEASE CAPSULES, 40 MG) FOR
THE TREATMENT OF PAPULOPUSTULAR ROSACEA TO BE ANNOUNCED WEEK OF
JULY 10, 2023
Source text for Eikon: ID:nGNX5wf4D0
Further company coverage: DERM.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi